论文部分内容阅读
观察AT501起搏器起搏预防和终止快速性房性心律失常的疗效。3例病窦综合征(SSS)患者,同时伴有快速性房性心律失常,置入Medtronic公司生产的AT501起搏器,术后1个月打开三种独立的起搏预防治疗功能和3个可程控的起搏终止治疗功能。经8～10个月的随访,患者的临床症状较术前明显改善,通过9790程控仪回顾心律失常发生事件,发现AT501起搏器对快速性房性心律失常的检测准确率为98%,起搏预防治疗功能和起搏终止治疗功能可减少快速性房性心律失常的发作,其中起搏终止治疗的成功率为56%,在270～360ms快速性房性心律失常检测区成功率为78%,在220～270ms快速性房性心律失常检测区成功率为40%。结论:初步临床应用表明,AT501起搏器置入后通过对起搏器的起搏预防和终止治疗功能合理程控,可安全、有效地减少快速性房性心律失常的发作。
AT501 pacemaker pacing to prevent and terminate the rapid atrial tachyarrhythmia effect. Three patients with sick sinus syndrome (SSS), accompanied by atrial tachyarrhythmia, were placed in an AT501 pacemaker manufactured by Medtronic Corporation. Three independent pacing preventive and therapeutic functions and three Programmable pacing termination of treatment. After 8 to 10 months of follow-up, the clinical symptoms of patients were significantly improved compared with preoperative, 9790 program-controlled instrument to review the incidence of arrhythmia and found that AT501 pacemaker detection rate of atrial tachyarrhythmia was 98% Stroke prevention and treatment of patency and termination of treatment can reduce the onset of atrial tachyarrhythmias, including pacing termination of the success rate of 56% in 270 ~ 360ms tachyarrhythmia detection zone success rate of 78% , In 220 ~ 270ms tachyarrhythmia detection area success rate was 40%. Conclusion: The preliminary clinical application shows that the AT501 pacemaker can be safely and effectively reduced the onset of atrial tachyarrhythmia by pacing the pacemaker prevention and termination of treatment.